ANA Test: Which Tests to Order Alongside Antinuclear Antibody

What ANA Actually Measures

The antinuclear antibody test detects immunoglobulins that bind to components of the cell nucleus. A positive result means the immune system has produced antibodies against nuclear material. The test itself does not tell you which specific antigen is targeted, how active any disease process is, or whether the patient has a defined autoimmune condition.

Results are reported as a titer (the highest dilution at which fluorescence is still visible) and a pattern (homogeneous, speckled, nucleolar, centromere, or peripheral). Both pieces of information guide which follow-up tests to order.

Titer Interpretation

| Titer | Clinical Significance | |---|---| | <1:40 | Negative; reported as negative by most labs | | 1:40 | Weakly positive; seen in up to 30% of healthy adults | | 1:80 | Positive threshold; requires clinical correlation | | 1:160 | Moderately positive; increases pre-test probability | | ≥1:320 | High titer; more strongly associated with defined autoimmune disease |

A 2012 position statement from the American College of Rheumatology noted that ANA testing should be used in the context of signs and symptoms of autoimmune disease, not as a population screen, because false-positive rates are high at low titers. [1]

Pattern Interpretation

The fluorescence pattern provides early directional information. A homogeneous pattern points toward anti-dsDNA or anti-histone antibodies and suggests SLE or drug-induced lupus. A speckled pattern points toward anti-Sm, anti-SSA/SSB, anti-RNP, or anti-Scl-70 antibodies. A nucleolar pattern raises concern for scleroderma. A centromere pattern is strongly associated with limited cutaneous systemic sclerosis (CREST syndrome).

Patterns narrow the differential but do not replace specific antibody testing. [2]

The Core Reflex Panel: What to Add When ANA Is Positive

When a patient has symptoms consistent with a connective tissue disease and returns a positive ANA at 1:80 or higher, most rheumatologists and ordering clinicians move immediately to an expanded panel. The exact composition varies by clinical picture, but a standard reflex panel includes the following.

Anti-Double-Stranded DNA (anti-dsDNA)

Anti-dsDNA antibodies are highly specific for systemic lupus erythematosus. Specificity for SLE exceeds 97% in most studies, though sensitivity is only 57-70%. [3] Titers of anti-dsDNA correlate with disease activity; rising titers often precede a lupus flare by weeks. This makes anti-dsDNA one of the few autoimmune antibodies useful for monitoring, not just diagnosis.

The 2019 European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) SLE classification criteria assign 6 points to high-titer anti-dsDNA, making it the single highest-weighted immunological criterion in the scoring system. [4]

Anti-Smith (Anti-Sm)

Anti-Sm antibodies target proteins in small nuclear ribonucleoprotein (snRNP) complexes. Like anti-dsDNA, anti-Sm is highly specific for SLE (specificity greater than 98%), but it is present in only 25-30% of SLE patients. A positive anti-Sm result alongside a positive ANA is considered strong evidence for SLE under the EULAR/ACR 2019 criteria. [4]

Anti-SSA (Ro) and Anti-SSB (La)

These antibodies are the primary markers for primary Sjögren syndrome. Anti-SSA is present in 60-80% of primary Sjögren patients and in up to 30-40% of SLE patients. Anti-SSB is more specific for Sjögren syndrome when present without anti-SSA. [5]

Anti-SSA is also clinically critical in pregnancy. Maternal anti-SSA antibodies cross the placenta and can cause neonatal lupus and congenital heart block, a potentially life-threatening fetal arrhythmia. The American College of Obstetricians and Gynecologists recommends testing for anti-SSA and anti-SSB in pregnant women with known or suspected autoimmune disease. [6]

Anti-Scl-70 and Anticentromere Antibodies

For patients presenting with skin thickening, Raynaud phenomenon, or dysphagia, the evaluation extends to scleroderma-specific markers. Anti-Scl-70 (anti-topoisomerase I) is associated with diffuse cutaneous systemic sclerosis and carries a higher risk of interstitial lung disease. Anticentromere antibodies are associated with the limited form (CREST syndrome) and a better overall prognosis. [7]

Anti-RNP (U1-RNP)

High-titer anti-U1-RNP antibodies, in the absence of anti-Sm and anti-dsDNA, are the hallmark of mixed connective tissue disease (MCTD). Anti-RNP is also present in a subset of SLE and scleroderma patients. When this antibody is positive alongside overlapping features of multiple connective tissue diseases, MCTD becomes the leading diagnosis. [8]

Complement Levels: C3 and C4

Complement testing is a direct window into immune complex activity. In SLE, circulating immune complexes activate and consume the complement cascade. C3 and C4 levels fall during active disease, a pattern called hypocomplementemia.

Why C3 and C4 Matter

A patient with positive anti-dsDNA, low C3 (normal range 90-180 mg/dL), and low C4 (normal range 16-47 mg/dL) has a strong biochemical fingerprint of active lupus nephritis. Serial C3/C4 measurements are used at most academic rheumatology centers to track disease activity over time. [9]

C4 is genetically complex. Some individuals carry null alleles at the C4A gene locus and therefore have constitutively low C4 without active lupus. Clinicians interpret isolated low C4 in the context of C3 and anti-dsDNA rather than in isolation. [10]

CH50 (Total Hemolytic Complement)

CH50 measures the functional activity of the entire classical complement pathway. A very low CH50 alongside low C3 and C4 is almost always pathological. CH50 is particularly useful when an inherited complement deficiency (C2 deficiency, the most common complement deficiency in Europeans) is suspected alongside SLE. [10]

CBC with Differential

A complete blood count with differential is not optional in any ANA-positive patient with symptoms. Autoimmune cytopenias are among the diagnostic criteria for SLE under both the 1997 ACR criteria and the 2019 EULAR/ACR criteria.

Specific findings to look for include:

• Leukopenia (<4,000 cells/mcL on at least two occasions): one of the hematological SLE criteria
• Lymphopenia (<1,000 cells/mcL): associated with active SLE and elevated anti-dsDNA
• Thrombocytopenia (<100,000 cells/mcL): may indicate immune-mediated destruction, prompting antiphospholipid antibody testing
• Hemolytic anemia with positive direct Coombs test: seen in 10-15% of SLE patients [11]

Comprehensive Metabolic Panel and Urinalysis

CMP: Detecting Renal and Hepatic Involvement

Lupus nephritis occurs in roughly 40-60% of SLE patients over the course of their disease. [12] An elevated serum creatinine or reduced eGFR on the CMP may be the first laboratory sign of renal involvement. Liver enzyme elevation (ALT, AST) points toward autoimmune hepatitis, a condition associated with ANA positivity, particularly the homogeneous pattern.

Urinalysis with Microscopy

Urinalysis with microscopy is one of the most informative and lowest-cost tests in the ANA workup. Active lupus nephritis produces a characteristic "active urinary sediment": red blood cell casts, white blood cell casts, proteinuria, and hematuria. Finding red cell casts in a patient with a positive ANA and elevated anti-dsDNA indicates class III or IV lupus nephritis until proven otherwise. A 24-hour urine protein or spot urine protein-to-creatinine ratio quantifies the degree of proteinuria. [12]

Inflammatory Markers: ESR and CRP

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are non-specific markers of systemic inflammation. Their utility in the ANA workup comes from the unusual pattern seen in SLE: ESR is often markedly elevated during a flare, while CRP may remain normal or only mildly elevated. [13]

A significantly elevated CRP in an SLE patient should raise concern for a concurrent bacterial infection rather than a pure lupus flare, because lupus itself tends not to drive CRP as high as infection does. This clinical pearl guides antibiotic decisions in febrile lupus patients.

Antiphospholipid Antibody Panel

Any ANA-positive patient with unexplained thrombosis, recurrent pregnancy loss, or thrombocytopenia warrants testing for antiphospholipid syndrome (APS). The diagnostic antibodies include:

• Lupus anticoagulant (a functional coagulation assay, not a specific antibody test)
• Anticardiolipin antibodies (IgG and IgM)
• Anti-beta-2 glycoprotein I antibodies (IgG and IgM)

The 2023 ACR/EULAR antiphospholipid syndrome classification criteria require at least one of these antibodies to be present on two occasions at least 12 weeks apart. [14] Antiphospholipid syndrome can occur in isolation (primary APS) or alongside SLE (secondary APS), and distinguishing the two changes long-term anticoagulation management.

Thyroid Antibodies

Autoimmune thyroid disease and connective tissue diseases share genetic risk factors and frequently co-occur. Between 10 and 30% of SLE patients have detectable thyroid peroxidase antibodies (anti-TPO) or thyroid-stimulating immunoglobulins. [15]

A TSH, free T4, anti-TPO, and thyroglobulin antibody panel adds minimal cost and can identify a concurrent autoimmune thyroiditis that may be contributing to fatigue, cognitive symptoms, and weight changes. These symptoms overlap heavily with lupus and Sjögren syndrome, making it easy to miss a second autoimmune condition.

Myositis Panel (When Muscle Symptoms Are Present)

Patients reporting proximal muscle weakness, muscle pain, or elevated creatine kinase (CK) alongside a positive ANA need evaluation for inflammatory myopathy. The myositis-specific antibodies include:

• Anti-Jo-1 (the most common anti-synthetase antibody; associated with interstitial lung disease and mechanic's hands)
• Anti-Mi-2 (classic dermatomyositis)
• Anti-MDA5 (associated with rapidly progressive ILD and amyopathic dermatomyositis)
• Anti-SRP (immune-mediated necrotizing myopathy)

Aldolase and CK should accompany the antibody panel, as they confirm active muscle inflammation. [16]

Drug-Induced Lupus: When to Consider Anti-Histone Antibodies

Drug-induced lupus erythematosus (DILE) is triggered by specific medications, most commonly hydralazine, procainamide, isoniazid, minocycline, and tumor necrosis factor (TNF) inhibitors. Anti-histone antibodies are present in more than 95% of procainamide-induced and hydralazine-induced lupus cases and only 50-80% of idiopathic SLE. [17]

A medication review is an integral part of the ANA workup. When the history includes one of the implicated drugs and anti-histone antibodies are positive with negative anti-dsDNA and anti-Sm, DILE is the working diagnosis. Stopping the offending drug typically resolves the syndrome within weeks to months.

Imaging and Biopsy: Beyond Blood Tests

Laboratory testing alone does not always establish a diagnosis. Two adjunctive steps deserve mention.

Chest Imaging

Interstitial lung disease complicates many connective tissue diseases, particularly scleroderma (up to 80% prevalence over the disease course), myositis with anti-synthetase syndrome, and SLE. A high-resolution CT (HRCT) of the chest identifies ground-glass opacities and fibrotic changes that blood tests miss. [18]

Renal Biopsy

When proteinuria exceeds 500 mg per day or an active urinary sediment is present alongside positive anti-dsDNA, a renal biopsy provides the tissue diagnosis that determines treatment intensity. The International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2018 classification divides lupus nephritis into six classes, each carrying different prognostic and therapeutic implications. [19]

When ANA Is Negative: What That Means

A negative ANA by IIF at 1:80 makes SLE unlikely but does not exclude it. Roughly 2-3% of SLE patients are ANA-negative at any given time, particularly those with predominantly skin or musculoskeletal disease. Sjögren syndrome patients with isolated anti-SSA positivity may also test ANA-negative on some solid-phase assays if those assays lack the Ro-60 antigen.

The ACR's "15 Choosing Wisely" recommendations advise against ordering an ANA subserologies panel (anti-dsDNA, anti-Sm, etc.) when the ANA itself is negative, because the pre-test probability is too low to justify the false-positive risk from each individual antibody test. [20]

A Practical Ordering Framework

The following stepwise approach reflects current rheumatology practice patterns and is organized by clinical presentation rather than by test name.

Step 1 (all ANA-positive patients with symptoms): anti-dsDNA, anti-Sm, anti-SSA, anti-SSB, anti-RNP, C3, C4, CBC with differential, CMP, urinalysis with microscopy, ESR, CRP.

Step 2 (add if specific features are present):

• Skin thickening, Raynaud, or dysphagia: anti-Scl-70, anticentromere, anti-RNA polymerase III
• Proximal muscle weakness or elevated CK: myositis panel (anti-Jo-1, anti-Mi-2, anti-MDA5, anti-SRP), aldolase
• Thrombosis, pregnancy loss, or thrombocytopenia: lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta-2 glycoprotein I IgG/IgM
• Fatigue, cold intolerance, cognitive symptoms: TSH, free T4, anti-TPO, thyroglobulin antibodies
• Implicated drug exposure: anti-histone antibodies

Step 3 (based on laboratory findings):

• Proteinuria greater than 500 mg/day or active sediment: renal biopsy referral
• Elevated CK or anti-synthetase positivity: EMG and muscle MRI before biopsy
• Respiratory symptoms or abnormal chest auscultation: HRCT chest and pulmonary function tests

The entire first-step panel can be ordered as a single "ANA reflex" or "connective tissue disease panel" at most major reference laboratories, reducing turnaround time and specimen handling errors.

Normal ANA Range and What Titers Mean Clinically

The term "normal ANA" is context-dependent. ANA positivity is not binary; it sits on a spectrum defined by titer and clinical presentation.

A titer of 1:80 is the standard positive threshold used by the American College of Rheumatology and most U.S. Reference laboratories. At this dilution, roughly 5% of the healthy adult population tests positive, a rate that rises with age. By age 65, ANA positivity at 1:40 is detected in more than 35% of healthy individuals. [1]

Titers of 1:320 or higher carry a meaningful increase in the probability of a defined autoimmune disease, but they still require clinical symptoms to be actionable. A 2016 study in Annals of the Rheumatic Diseases found that high-titer ANA positivity preceded the clinical onset of SLE by a median of 3.3 years in some patients, suggesting a prodromal autoimmune state. [21]

You cannot "lower" an ANA titer through lifestyle changes or supplements. The titer reflects immunological activity and changes with disease activity or, in the case of DILE, with drug removal. Treating the underlying condition with hydroxychloroquine, glucocorticoids, or immunosuppressants such as mycophenolate mofetil may reduce ANA titer over months to years, but titer reduction is a secondary effect, not a treatment goal by itself. Attempting to "raise" a low ANA has no clinical rationale; a low or negative ANA in a symptomatic patient should prompt investigation of ANA-negative autoimmune diseases rather than efforts to increase the titer.